Roche Q3 Report 2022

• Group sales up 2% at constant exchange rates (CER) and 1% in Swiss francs; as expected, significantly lower COVID-19-related sales in both divisions in the third quarter
• Sales in the Pharmaceuticals Division at the previous year’s level with significantly lower sales of COVID-19-related products (Ronapreve and Actemra/RoActemra) and losses to biosimilars, offset by strong growth of newer medicines
• Sales in the Diagnostics Division rise 6%; base business remains strong; as expected, demand for COVID-19 tests sharply down in third quarter

Highlights in the third quarter:

• EU approval for Vabysmo (severe eye diseases)
• US approvals for Xofluza (influenza in children)
• Launch of a digital PCR diagnostic platform and of COVID-19, skin and breast cancer tests
• “Breakthrough Device Designation” granted for Alzheimer’s blood tests

Group sales

Sales were up in Japan (+7%), mainly due to supply of Ronapreve to the government, followed by sales growth of Evrysdi, Hemlibra, Polivy and Enspryng. This more than offset the impact of government price cuts and biosimilars.